Authors’ Reply to “The Challenges of Studying Peripheral Vestibular Vertigo”

  • Arne W. Scholtz
  • Gerhard WeisshaarEmail author
Letter to the Editor

Dear Editor,

We are grateful to Dr. Naples [1] for his constructive feedback on our article in Clinical Drug Investigation [2], and would like to take this opportunity to address the points raised regarding the particular challenges of studying peripheral vestibular vertigo.

In general, clinical studies on patients with vertigo, whether predominantly of peripheral or central origin, are indeed challenging for a number of reasons. Vertigo is not a disease entity, but a complex set of numerous single symptoms, each subjectively experienced and reported by individual patients. Furthermore, regarding the terminology of vestibular symptoms, there are still different perceptions among experts dealing with vertigo (e.g., otolaryngologists, neurologists) and between countries or geographic regions. Only in 2009, the Committee for Classification of Vestibular Disorders of the Bárány Society published a consensus document in a first attempt to define, harmonize, and classify key vestibular...


Compliance with Ethical Standards


No funding was received to prepare this letter.

Conflict of interest

Arne W. Scholtz has no conflicts of interest to declare. Gerhard Weisshaar is an employee of Hennig Arzneimittel.


  1. 1.
    Naples JG. The challenges of studying peripheral vestibular vertigo. Clin Drug Investig. 2019. CrossRefGoogle Scholar
  2. 2.
    Scholtz AW, Hahn A, Stefflova B, et al. Efficacy and safety of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg vs betahistine dihydrochloride 16 mg in patients with peripheral vestibular vertigo: a prospective, multinational, multicenter, double-blind, randomized, non-inferiority clinical trial. Clin Drug Investig. 2019;39(11):1045–56.CrossRefGoogle Scholar
  3. 3.
    Bisdorff A, von Brevern M, Lempert T, Newman-Toker DE. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res. 2009;19:1–13.PubMedGoogle Scholar
  4. 4.
    Kruschinski C, Kersting M, Breull A, Kochen MM, Koschack J, Hummers-Pradier E. Frequency of dizziness-related diagnoses and prescriptions in a general practice database. Z Evid Fortbild Qual Gesundh Wesen. 2008;102:313–9. (Article in German).CrossRefGoogle Scholar
  5. 5.
    Scholtz AW, Steindl R, Burchardi N, Bognar-Steinberg I, Baumann W. Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis. A randomized, double-blind, non-inferiority study. Clin Drug Investig. 2012;32(6):387–99.CrossRefGoogle Scholar
  6. 6.
    Novotný M, Bognar-Steinberg I, Baumann W. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Menière’s disease: post hoc non-inferiority analysis of a prospective, randomized, double-blind study. Arch Sensol Neurootol-ASN. 2011:6 [online]. Accessed 13 May 2019.
  7. 7.
    Scholtz AW, Ilgner J, Loader B, Pritschow B, Weisshaar G. Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien Klin Wochenschr. 2016;128:341–7. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.ENT ClinicMedical University of Innsbruck, and ENT Center for VertigoInnsbruckAustria
  2. 2.Hennig Arzneimittel GmbH & Co. KGFloersheim am MainGermany

Personalised recommendations